Leading Chinese Stem Cell Therapy Provider Awarded Three ISO9001 Certifications for Stem Cell Technology Quality Management System

TAIZHOU, China, April 2 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, has been awarded ISO9001 certification by the International Organization for Standardization ("ISO"). This internationally recognized designation signifies Beike has established a Quality Management System (QMS) that complies with ISO9001 standards. To be certified to these standards, Beike's stem cell preparation laboratory was recently assessed by auditors of the China Quality Certification Centre (CQC) and joins Beike's Jiangsu Province Stem Cell Bank and processing laboratory as the latest Beike facility to achieve the ISO9001 recognition. The Jiangsu Province Stem Cell Bank and Regenerative Medicine Base was the first comprehensive storage facility to receive authentications for both banking and cell processing systems.

TAIZHOU, Jiangsu, China, January 6 – The Jiangsu Government’s Science and Technology Department has announced a $1.8 million grant - the Jiangsu Technological Achievements Transformational Grant - to support the research and development of human umbilical cord mesenchymal stem cell (hUC-MSC) technologies. The grant recipient and administrator, Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com), is working with Jiangsu University and Nanjing University’s Drum Tower Hospital to fulfill the grant’s requirements.

This grant marks the start of the second stage of Beike’s stem cell engineering industrialization project. The project’s first phase began in May 2008, when Beike opened an 1,800 square-meter stem cell bank in Taizhou’s China Medical City district. In the second phase, the bank will be used as a library for storing and indexing hUC-MSC samples. In April 2009, Beike broke ground on its 20,000 square-meter Stem Cell Regenerative Medicine Industrial Complex, the world’s largest stem cell storage and processing facility. Beike will use a portion of the Jiangsu Technological Achievements Transformational Grant to outfit this complex with over 80 specialized pieces of equipment including fully automated enzyme immunoassay analysis systems, carbon dioxide incubators, and cell viability analyzers.

Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India

NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D., Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd. (http://www.beikebiotech.com ), spoke at a conference on High-Risk Diabetic Foot Care in New Delhi, India, November 22, 2009. Beike is China's leading stem cell research and regenerative medicine company.

The conference, organized by the Indian Podiatry Association (IPA), aimed to help podiatrists and researchers with an interest in foot disease to "update, interact, modernize and catch up with the advancing pace of scientific development in the field of podiatry." Dr. Jiang's talk, titled "Umbilical Cord Mesenchymal Stem Cell and Clinical Application Prospects in Diabetic Foot Disease," outlined the promise of stem cells in the healing of diabetic wounds and diabetic foot pathology.

"I am excited to have had this opportunity to discuss the role that stem cell therapy can play in healing diabetic wounds and related foot conditions," said Dr. Susan Jiang, speaking after the Conference. "India is one of the first countries to put forth clear and practical guidelines on the clinical use of stem cells. It has also been at the forefront in embracing this new technology, and utilizing its potential clinical applications. Together with leading clinicians in the field, Beike India is preparing a clinical trial of stem cell treatment in diabetic foot disease. Our pilot studies in China suggest that stem cell treatment will become a very practical and effective clinical intervention. We are happy to share our observations from our stem cell therapy studies with the Indian clinical community."

Taizhou, Jiangsu, China, 7 April 2009 – Jiangsu government’s China Medical City (CMC) and Shenzhen Beike Biotechnology Co. Ltd.  (http://www.beikebiotech.com) broke ground on the 20,000 square-meter Stem Cell Regenerative Medicine Industrial Project of National Bio-Industry Base (NBPD).  This facility will house China’s first comprehensive regenerative medicine technology center and its largest international stem cell bank.

The NBPD facility is part of multi-stage project that consists of industry partnerships aimed at providing a central research zone for China's regenerative medicine and bio-medical industry.  Groups associated with this biotechnology incubation joint-project include those from Fudan University, Huazhong Science and Technology University, Nanjing University Medical School, Jiangsu University, Shanghai Jiao Tong University and Jiangsu Provincial People's Hospital.